A statement released earlier today by Needham & Company LLC about Vascular Solutions, Inc. (NASDAQ:VASC) bumps the target price to $58.00
- Updated: October 8, 2016
Stating a potential upside of 0.23%, Needham & Company LLC upped the price target of Vascular Solutions, Inc. (NASDAQ:VASC) to $58.00
Boasting a price of $47.11, Vascular Solutions, Inc. (NASDAQ:VASC) traded -1.35% lower on the day. With the last stock price close up 14.45% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. VASC has recorded a 50-day moving average of $48.49 and a 200-day moving average of $41.58. 90,344 shares of VASC were exchanged, down from an average trading volume of 113,338
See Chart Below
Vascular Solutions, Inc. has a 52 week low of $24.34 and a 52 week high of $50.72 with a P/E ratio of 88.13 The company’s market cap is currently $0.
About Vascular Solutions, Inc. (NASDAQ:VASC)
Vascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company's product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company's product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.